Abstract
Fourteen patients receiving a second graft were treated ultimately lead to serum sickness [17, 18] and/or deposwith an antiglobulin preparation they had not been given ition of CIC on the kidney basement membrane and during the first transplantation, and three were treated in the skin.
without ATG/ALG.
We have developed an ELISA assay to measure the We took into account two clinical immunological events: production of anti-rabbit and anti-horse globulins anti-first serum sickness, and second rejection ( Table 2) . Patients bodies of IgG, IgA, IgM isotype in renal transplant showing clinical symptoms of fever, rash and/or arthralgia recipients. This technique was applied before and after were considered to be suffering from serum sickness. transplantation to determine pre-and post-transplant Rejection was defined as the occurrence of at least one immunization of the patients against rabbit or horse biopsy-proven acute rejection during the first month posttransplant. Sixteen patients developed serum sickness in a globulins, as well as the correlation with clinical period of 9±1 days after transplantation; they were all first findings. transplant recipients. Sixty patients (50 first and 10 second transplants) presented a rejection episode.
Blood samples were obtained before and/or after renal
Subjects and methods
transplantation. Sera were stored at −20°C until use.
Serum samples Assay of anti ALG and anti ATG human immunoglobulins G, A, M
Two hundred and forty serum samples from 111 kidney allograft recipients ( 72 males, 39 females, mean age 44 years, range 19-72 years) were studied. Of these 111 kidney trans-Ninety-six-well microplates ( Maxisorp, Nunc, Roskilde, Denmark) were coated with 100 ml/well of the ATG or ALG plants ( Table 1) , 91 were primary transplants and 20 were second transplants ( 16 kidneys and 4 hearts as first used for patients' treatment, diluted in 0.1 M sodium carbonate bicarbonate buffer pH 9.6. The optimal concentration transplants).
Details on the immunosuppressive treatments are given in used, previously established by checkerboard assay, was 0.5 mg/ml for ATG (rabbit) and 1 mg/ml for ALG ( horse). Table 1 . All patients received a 2 mg/kg loading dose of azathioprine on the day of transplantation. For 72 patients The plates were incubated overnight at 4°C and washed three times with phosphate-buffered saline (PBS ) pH 7.4. Nonin first transplantation, induction immunosuppression consisted of 10-15 days of treatment with polyclonal antibodies: specific binding sites were blocked with 200 ml/well of 5% dry milk in PBS for 30 min at 37°C. One hundred microlitres rabbit ATG, horse ALG or ALG and ATG (Pasteur Mérieux Sérums et Vaccins, France) started postoperatively in associ-of serum samples diluted 15100 in PBS-Tween-BSA (bovine serum albumin, Sigma Chemical, CO, St Louis, MO) were ation with methylprednisolone (40 mg/day). Polyclonal antibodies were used with a dose adjusted by CD3+ lymphocytes then added to each well in duplicate. After incubation at 37°C for 45 min, the plates were washed three times. Goat daily monitoring. Cyclosporin was introduced when the serum creatinine concentration was lower than 230 mmol/l, anti-human IgA, IgG or IgM conjugated to horseradish peroxidase ( ICN biochemicals Inc., Costa Mesa, CA) diluted and the initial dose was 6 mg/kg/day (with target whole blood levels of 150-200 mg/l by the monoclonal assay 151000, 1510 000 and 151000 respectively in PBS-BSA were added and left to incubate for 45 min at 37°C. The plates method ). were washed and 100 ml of a freshly prepared substrate solution of 6 mg of o-phenylenediamine dihydrochloride (OPD, Sigma Chemical ) and 25 ml of H 2 O 2 in 12 ml of 0.1 M citrate/citric acid pH 5.5 were placed in each well. The reaction was stopped with 50 ml of H 2 SO 4 2N. The absorbance was read at 492 nm on a Multiskan II spectrophotometer (Flow Laboratories, Helsinki, Finland). A reference pool of normal human serum was used, also in duplicate, in each plate as calibrator.
Results were expressed as the mean absorbance value of the sample divided by the mean absorbance value of the calibrator.
Follow-up of several patients before and after transplantation showed that some produced antibodies directed to antilymphocyte globulins, while others had extremely stable low levels ( Figure 1 ). This confirmed the assay reproducibility and specificity.
Statistical analysis
Chi2 test was used to compare the proportions of patients who produced antibodies before and after transplantation. Anova, paired Student's t tests, and Fisher tests were used to compare xenoantibody levels, with P values<0.05 considered statistically significant.
Results

Pretransplant antiglobulin antibodies
First transplants. Patients who received primary transplants had never been treated with ATG or ALG. The levels of anti-ATG and anti-ALG antibodies were Fig. 1 . Examples of antiglobulin antibody levels follow-up before evaluated in this population, and the mean+2 SD (day 0) and after transplantation. Figures in the abscissa indicate the days post-transplantation, and in the ordinate, antibody levels obtained for each isotype was used to define positivity expressed as the ratio between the mean absorbance value of the thresholds. This is reported in Table 3 , which also sample divided by the mean absorbance value of a calibrator of indicates overall sensitization rates for each isotype in pooled normal human serum. Anti-ATG antibodies are represented the whole pretransplant population. ( 8.9%) respectively as well as their partition among the subgroups of patients who received ATG, ALG, or no globulins during their first transplantation. This to the type of initial immunosuppressive treatment figure indicates the absence of significant difference received, as summarized in Table 4 . Patients who were between the various groups of therapy applied.
given ATG, either alone or after ALG, had significantly Second transplants. The rate of sensitization before higher levels of anti-ATG IgM, anti-ALG IgG and second transplantation was slightly higher for anti-anti-ALG IgM post-transplantation. As shown in ATG antibodies ( 15%) than for anti-ALG antibodies Table 3 , the incidence of transplanted patients with ( 10%) ( Figure 2 ). significant levels of anti-ATG or anti-ALG antibodies increased after transplantation. Overall, 32% of these Post-transplant antiglobulin antibodies patients had at least one isotype of anti-ATG antibodies and 29% had at least one isotype of anti-ALG First transplants. The levels of antiglobulin antibodies were compared in paired series of patients according antibodies ( Figure 2) . significant increase in anti-ATG IgA and IgM levels ( Table 4 ) . However, using the significance thresholds defined with pretransplant samples, there was no significant increase in the proportion of sensitized patients after transplantation ( Figure 2) . Second transplants. No significant modification of anti-ATG or anti-ALG levels were noted in patients who received a transplant for the second time (data not shown). The incidence of sensitized individuals increased slightly (Figure 2 ), but was not statistically significant. in this group had to receive both types of antiglobulins (50%), compared to patients who did not develop serum sickness (25%). Antibody levels could be In the smaller group of patients who received ALG, alone or before ATG, only anti-ALG IgA and IgM assessed post transplantation in 14 of these patients.
Clinical events
The development of serum sickness was noted in levels increased significantly (Table 4 ) . Similarly, the incidence of sensitized individuals after ALG treat-one (11%) of the presensitized patients (at least one antibody). The proportion of sensitized patients ment, who had significant levels of at least one isotype, reached 33 and 39% for anti-ATG and anti-ALG increased to 71% after transplantation (P=0.02) while only 37% of the patients who had received ATG or respectively (Figure 2 ) . The difference failed to reach statistical significance owing to the smaller size of ALG but did not develop serum sickness had significant levels of at least one isotype of antilymphocyte this group.
Patients who received no antiglobulin and could be globulin antibodies after transplantation. The mean follow-up time for patients with serum sickness was tested both before and after transplantation had a Table 5 . Post-transplant antibody levels (mean±SE) in patients who known to differ widely in their specificity and activity developed serum sickness or not [5, 6] . One of the aims of our study, which was performed [20] , who also showed an increase of specific IgM in IgM ALG 2.19±0.77 0.07 1.24±0.14 heart recipients who received ATG as prophylactic treatment. Waller et al. [21 ] reported the production of xenoantibodies of the IgG and IgM isotypes and rather short (24±9 days), suggesting the possibility of Hiemstra et al. [22] , using an ELISA technique, dema later increase of antibody titres. The levels of anti-onstrated the presence of IgA to rabbit ATG in transglobulin antibodies of IgM isotype increased signific-planted patients. In our study, assaying antiantly in patients who developed serum sickness (P= ATG/ALG IgM and IgA seems to be more important 0.03 and P=0.04 for anti-ATG and anti-ALG respect-than measuring specific IgG levels, as we only observed ively; paired t tests), while IgA was the significantly significant variations in IgG levels in one of the subincreased isotype in patients who did not (P=0.04 and groups tested. However, immunosuppression by itself P=0.03 for anti-ATG and anti-ALG respectively; could be involved in deregulating the suppression of paired t tests). Table 5 shows that post-transplantation anti-animal protein clones, as significantly higher levels anti-ATG and anti-ALG antibody levels also differed of anti-ATG IgA and IgM were observed in the group between patients who developed serum sickness and of primary transplant who received other immunothose who did not.
suppressive treatments than antiglobulins. Among first transplant patients who received ATG
The incidence of patients with significant levels of or ALG, there was no statistically significant difference pretransplant anti-ATG antibodies was slightly higher (P=0.06) in the incidence of rejection episodes between in the second-graft recipients. In this group of patients, the patients who developed serum sickness (69%) and the number of recipients with xenoantibodies increased those who did not (45%), although there was a trend after transplantation but without statistical significance indicating a possibly higher risk of rejection for the and the antibody levels did not differ after the second former.
transplantation. It must, however, be emphasized that None of the patients who received a second trans-the patients were treated with a different antiglobulin plant developed serum sickness. preparation than during their first transplantation. No difference was noted in the incidence of postPretransplant antibodies to ATG and/or ALG levels transplantation antiglobulin antibodies, between could also be detected in first transplant recipients who patients who presented a rejection episode and those had never been treated with such globulins. Indeed, who did not.
we observed overall pretransplantation sensitization rates of 2.2-5.6% in primary recipients. This preimmunization against animal proteins could be due to Discussion the contact with rabbits or horses that some people may have in their environment, or to diet antigens, as humans can produce antibodies against food proteins This study reports on the assay of human IgG, IgA and IgM to prophylactic immunosuppressive horse [23] . Niblack et al. [14 ] have previously shown that patients produced antibodies more frequently to horse and rabbit globulins (ALG and ATG) in serum samples of kidney recipients, before and after trans-serum than to rabbit proteins. This could be related to a difference of immunogenicity between the two plantation. Each serum sample was tested in ELISA for three isotypes, towards both the anti-horse and species. Amemiya et al. [15] have also demonstrated in volunteers and transplant recipients the occurrence anti-rabbit globulins. In the 1970's, several studies investigated for anti ALG or anti ATG antibodies of antibodies against horse, goat, or rabbit proteins.
It is interesting to note that high IgA levels were often production to demonstrate the immunogenicity of antilymphocyte serum preparations but patient numbers pre-existing, which would be consistent with oral or at least mucosal immunization, occurring through meat were small (5-30), and different techniques such as radio immunoassay or ELISA were used [16, 19] . Even consumption or environmental exposure to these animals [24 ] . more recent studies [27 ] report variable results depending on the investigating laboratory. Moreover,
The clinical significance of pre and post-transplant anti-ALG or anti-ATG antibodies was addressed by most of these studies were performed with ATG and ALG prepared by other manufacturers than Mérieux, our study. No clear evidence for a negative effect of xeno-immunization on the rate of rejection episodes and the various preparations of such antiglobulins are
